FORT COLLINS, Colo. — PhotonPharma Inc., a biopharmaceutical company pioneering personalized cancer immunotherapies, today announced that patient recruitment has opened for its Phase 1 clinical trial evaluating Innocell™ in patients with recurrent epithelial ovarian cancer. The trial for Innocell, the investigational product, is registered with ClinicalTrials.gov under identifier NCT06366490 The clinical...

REDWOOD CITY, Calif. — Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced the publication of results from a prior Phase 2 clinical study evaluating burixafor (GPC-100/TG-0054), a highly selective CXCR4 inhibitor, in the journal Annals of Hematology. The manuscript, titled “Burixafor, a CXCR4...

OCALA, Fla. — AIM ImmunoTech Inc. (NYSE American: AIM)(“AIM” or the “Company”) today reported positive data in a year-end update from the ongoing Phase 2 clinical study evaluating AIM’s drug Ampligen® (rintatolimod) combined with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX...